218 patents
Page 11 of 11
Utility
Pyrrolopyrimidine derivatives as TAM inhibitors
30 Dec 19
Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
Filed: 10 Jul 18
Utility
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
23 Dec 19
The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAKs) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Wenqing Yao, David M. Burns, Jincong Zhuo
Filed: 16 Feb 17
Utility
Cyclopropylamines as LSD1 inhibitors
23 Dec 19
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
Liangxing Wu, Chunhong He, Ding-Quan Qian, Bo Shen, Wenqing Yao
Filed: 17 Nov 16
Utility
Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors
18 Nov 19
Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
Filed: 18 Oct 18
Utility
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
18 Nov 19
Yun-Long Li, Andrew P. Combs
Filed: 23 Aug 18
Utility
Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
11 Nov 19
The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
Jincong Zhuo, Chunhong He, Wenqing Yao
Filed: 1 May 18
Utility
1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
11 Nov 19
The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
Filed: 20 Mar 18
Utility
Heterocyclic compounds as PI3K-γ inhibitors
11 Nov 19
Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
Filed: 24 Jul 18
Utility
Tricyclic heterocycles as BET protein inhibitors
4 Nov 19
Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers
Filed: 26 Feb 18
Utility
Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
4 Nov 19
The present invention provides active metabolites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
James D. Rodgers, Argyrios G. Arvanitis, Jack Guoen Shi, Stacey Shepard
Filed: 24 Apr 17
Utility
Processes of preparing a JAK1 inhibitor and new forms thereto
21 Oct 19
Jiacheng Zhou, Zhongjiang Jia
Filed: 21 Sep 17
Utility
Bicyclic heterocycles as FGFR inhibitors
21 Oct 19
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Liang Lu, Wenqing Yao, Chunhong He, Fenglei Zhang
Filed: 1 Jul 18
Utility
Heterocyclic compounds useful as Pim kinase inhibitors
21 Oct 19
The present application is concerned with heterocyclic compounds that inhibit the activity of Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancers and other diseases.
Oleg Vechorkin, Yun-Long Li, Alexander Sokolsky, Anlai Wang, Wenyu Zhu, Jincong Zhuo
Filed: 24 Jan 18
Utility
Tricyclic heterocycles as bet protein inhibitors
14 Oct 19
The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
James D. Rodgers, Stacey Shepard, Haisheng Wang, Lixin Shao
Filed: 27 Aug 17
Utility
Pyrrolotriazine compounds as TAM inhibitors
14 Oct 19
Yun-Long Li, Xiaozhao Wang, Chunhong He
Filed: 3 May 18
Utility
Bipyrazole derivatives as JAK inhibitors
7 Oct 19
Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei
Filed: 14 Feb 18
Utility
Pyrazolopyridine compounds and uses thereof
7 Oct 19
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Oleg Vechorkin, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
Filed: 3 Dec 18
Utility
Pyrimidinones as PI3K inhibitors
30 Sep 19
The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
Filed: 22 Apr 18